A company is changing the imaging industry with new software that far exceeds all current mammography technology. This breakthrough technology reveals the make up of the entire breast, including what dense tissue usually hides, allowing doctors to see a level of detail unparalleled to anything before. This new approach to machine learning allows both the clinician and artificial intelligence engines to see what is really there and differentiate early stage cancer and other structural abnormalities potentially smaller than 1mm. This level of detail has the potential to provide clinicians significant and critical time advantage, thereby enabling better outcomes: fewer false positives…
Author: Brett Johnson
A new breakthrough energy-based cancer therapy has the ability to kill cancer cells with no side effects in five different cancer cell types: breast, prostate, and the pancreas. This new therapy induces rapid cell death in over 80% in just two hours. It utilizes a drug combined with a certain light wavelength to produce a chemical reaction, then injected into a cancerous tissue, which disseminates, resulting in high acidity in the cancer cells, and eventually, death. The drug mixed with their technology shows no adverse side effects and been successful at killing different types of cancer cells in their petri…
A real-time, in vivo imaging platform guides surgeons during cancer surgery. This breakthrough technology illuminates cancer cells and other diseased tissues at the molecular level, allowing surgeons to take action and better patient outcomes. Currently, there is a technological gap at the molecular level. Surgeries are being completed without being able to distinguish between healthy and cancerous tissue. This technology solves the problem, so surgeons can complete their surgeries with the ability to differentiate between tissues and have better accuracy in removing all cancerous tissue. Currently, the company is focused on breast cancer in their testings, but want to continue…
Clifford Reid is the founding CEO of Travera. Previously, Dr. Reid was the founding Chairman, President and Chief Executive Officer of Complete Genomics (NASDAQ:GNOM), a leading developer of whole human genome DNA sequencing technologies and services. Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT), a member of the MIT Corporation Development Committee, and an advisor to Warburg Pincus. He earned a S.B. in Physics from MIT, an MBA from the Harvard Business School, and a Ph.D. in Management Science and Engineering from Stanford University. Brett Johnson: So tell us…
Travera’s new technology can predict how patients will respond to hundreds of different drugs or drug combinations before the patients even take the drugs. Their new measurement tool, the Suspended Microchannel Resonator (SMR), reveals cancer cells’ responses to effective drugs faster than ever before. Travera tests on-label drugs, off-label drugs, and investigational drugs, to maximize drug quality and effectiveness for patients and to save them from unnecessary toxicity. By doing so, Travera can pinpoint the right drugs within <2 days, even though it will take many weeks to work in the patient’s body, and thus, is moving oncology from being…
Mature pipeline of biopharmaceuticals for rare diseases. Government funding for biodefense business. Soligenix is a two-segment business. They have a biotherapeutics rare disease segment focused on cancer, cancer supportive care and inflammation and a separate vaccine/biodefense segment of business funded entirely by the U.S. government, focused on medical countermeasures for military and civilian use. See Soligenix’s Profile.
June 7, 2019, by NCI Staff Smoldering myeloma is a slow-growing type of multiple myeloma, a form of cancer in which abnormal plasma cells (purple) make too much of a single type of antibody. The drug lenalidomide (Revlimid) may delay the development of multiple myeloma in individuals with smoldering myeloma that is at high risk of progressing to cancer, according to preliminary results from a clinical trial. Smoldering myeloma is a precancerous condition that alters certain proteins in blood and/or increases plasma cells in bone marrow, but it does not cause symptoms of disease. About half of those diagnosed with the condition, however, will develop multiple myeloma within 5 years.…
JUNE 4, 2019 NFCR WRITER DAVID PERRY BLOG Ask any parent about their child fighting cancer and words like “nightmare” and “helpless” will almost certainly be part of the conversation. Within pediatric cancer medicine, the entire field faces the brutal reality that chemotherapy, surgery and most other cancer treatments are not designed for children. This can be somewhat understandable, since cancer is predominantly an adult disease. There are more than 100 kinds of cancer, yet the American Cancer Society lists just eight as common among children. Yet pediatricians cannot, on the fly, convert adult therapies to use for child patients. Use too little of…